Vectura Fertin Pharma

Vectura Fertin Pharma is the healthcare and wellness business unit of Philip Morris International, formed by the integration of Vectura Group and Fertin Pharma. The company specializes in the development and manufacturing of innovative delivery systems for inhaled and oral medications, including dry powder inhalers, pressurized metered-dose inhalers, and medicated chewing gums. Its business model combines a proprietary pipeline of drug-device combination products with CDMO services for global pharmaceutical partners. Key areas of focus include respiratory health, smoking cessation, and rapid-onset treatments for acute conditions like myocardial infarction. In 2024, the company underwent a significant transition as its respiratory-focused Vectura assets were divested to Molex.